Printer Friendly

STRESSGEN BIOTECHNOLOGIES GAINS EXCLUSIVE WORLDWIDE RIGHTS FROM MIT TO NEW CLASS OF IMMUNE STIMULANTS

 VICTORIA, British Columbia, Oct. 15 /PRNewswire/ -- StressGen Biotechnolgies Corp., based here, today announced it received exclusive rights from the Massachusetts Institute of Technology (MIT) and the Whitehead Institute for Biomedical Research (WIBR) to commercialize "stress proteins" -- newly discovered immune stimulants. The technology will form the basis of a highly potent class of genetically engineered vaccines for the prevention of infectious diseases and therapeutics for the treatment of cancer.
 Under the signed agreement, StressGen is the sole and exclusive licensee of several United States and international patent applications filed jointly by MIT, WIBR and the Medical Research Council of Great Britain, allowing the company to fully develop and commercialize pharmaceutical products based on stress proteins. Financial details were not disclosed.
 "After extensive due diligence and market evaluation, we chose this technology because of its broad utility and application to medicine, especially infectious diseases such as tuberculosis and many types of cancer," said That T. Ngo, Ph.D., StressGen's chairman and chief executive officer. "This agreement provides StressGen with a key component in its strategy to become the leading stress protein-based biopharmaceutical company."
 Stress Proteins
 Research pioneered by StressGen's founders has focused on a unique class of proteins that all organisms make in response to life- threatening heat or chemical toxins at the cellular level. Originally called "heat shock proteins," these molecules also play a key role during non-stressful conditions and are essential to helping maintain the three-dimensional folding of cellular proteins necessary for life. Recent studies have shown that these "molecular chaperones" -- also known as stress proteins -- play a central role in the body's defense against disease.
 Results of studies during the past five years demonstrate that the immune system is primed to respond powerfully to the stress proteins of invading pathogens. Functioning as an "early warning system" to defend against microbial infections and other forms of "non-self," stress proteins are "super antigenic": they strongly stimulate the production of disease-fighting antibodies, as well as specialized white blood cells against disease.
 StressGen is applying proprietary technology based on the universal ability of stress proteins to rapidly and specifically activate the immune system. The company's Unigen(TM) -- "universal antigen" -- technology is aimed at using genetically engineered stress proteins to unlock the power of the immune system to prevent and treat disease. StressGen is developing infectious-disease vaccines, therapeutic cancer vaccines, vaccines adjuvants and carriers; and manufactures and markets stress-response reagents to researchers worldwide.
 -0- 10/15/93
 /CONTACT: Richard M. Glickman, president & COO of StressGen Biotechnolgies, 604-744-2811; or Charles Versaggi, Ph.D. of Gable/Versaggi BioCommunications, 408-358-4162/


CO: StressGen Biotechnologies; Massachusettes Institute of Technology;
 Whitehead Institute for Biomedical Research ST: British Columbia, Massachusettes IN: MTC SU:


NY-LM -- SD001 -- 2591 10/15/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 15, 1993
Words:451
Previous Article:BELL ATLANTIC AND DSC RENEW CONTRACT FOR THE DELIVERY OF NEXT GENERATION DIGITAL LOOP CARRIER SYSTEMS
Next Article:INTERNATIONAL TOTALIZATOR SYSTEMS RECEIVES INCREASE IN ADD-ON ORDER PLACED BY MALAYSIAN LOTTERY CUSTOMER
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters